Traders should monitor the AACR presentation for additional data clarity and assess potential for accelerated development or partnership expansion. Positive pCR rates in PD-L1-high patients may re-rate the stock despite prior funding concerns, especially if durability and safety data are favorable.
Price Chart
Executive Summary
Innate Pharma announced interim Phase 2 results from its MATISSE trial showing a 35.7% pathological complete response (pCR) rate in PD-L1≥1% NSCLC patients and 50% in PD-L1≥50% patients treated with IPH5201 plus durvalumab and chemotherapy, positioning the combination as a promising perioperative therapy. These results will be presented at AACR 2026, catalyzing further development in a high-unmet-need setting.
Key Facts
- Interim results from 40 patients in the MATISSE Phase 2 trial show a 35.7% pCR rate in PD-L1≥1% and 50% pCR in PD-L1≥50% resectable NSCLC patients treated with IPH5201 + durvalumab + chemotherapy.
- Results are superior to historical benchmarks of durvalumab + chemotherapy alone, supporting enhanced anti-tumor immune response with dual CD39 and PD-L1 inhibition.
- IPH5201 is a first-in-class anti-CD39 monoclonal antibody co-developed with AstraZeneca.
- Data will be presented at the AACR 2026 Clinical Trials Plenary Session on April 21, 2026.
- The trial continues to enroll PD-L1-positive patients based on these encouraging signals.
Financial Impact
Potential increase in valuation due to de-risking of IPH5201 development; enhances partnership or licensing prospects with AstraZeneca. No direct revenue impact yet as trial is ongoing.
Risk Factors
- Results are interim and based on a small sample size (40 patients); final outcomes may differ.
- Prior 20-F filing highlighted a funding gap and going concern risk, meaning positive data alone does not resolve near-term cash runway issues without follow-on financing or partnership.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-025688 |
| Document: a2604176kincorporatediph.htm | 0001628280-26-025688 |
| Document: 0001628280-26-025688-index-headers.html | 0001628280-26-025688 |
| Document: 0001628280-26-025688-index.html | 0001628280-26-025688 |
| Document: 0001628280-26-025688.txt | 0001628280-26-025688 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 23w ago | 6-K | $2.25 $1.65 | ▼ −26.67% | ▼ −32.96% | $1.51 (−32.93%) |
May 13, 2026 23w ago | 6-K | $1.50 $1.65 | ▼ −10.00% | ▼ −5.56% | $1.51 (−0.60%) |
May 6, 2026 24w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +7.94% | $1.51 (+0.60%) |
Apr 23, 2026 26w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +4.98% | $1.51 (+0.60%) |
Apr 17, 2026 27w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +3.86% | $1.51 (+0.60%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 8, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +9.72% | $1.51 (+9.91%) |
Apr 3, 2026 29w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +6.71% | $1.51 (+9.91%) |
Apr 1, 2026 29w ago | 20-F | $1.37 $1.65 | ▼ −20.17% | ▼ −6.80% | $1.51 (−9.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers